期刊
ANTIBIOTICS-BASEL
卷 10, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/antibiotics10111318
关键词
ceftazidime/avibactam; B-lactams; B-lactamase inhibitor; multi-drug resistance
资金
- Department of Clinical Microbiology, Christian Medical College, Vellore and Wockhardt Research Centre, India
This study revealed the development of ceftazidime/avibactam resistance in K. pneumoniae expressing OXA-48-like beta-lactamases, with mutations in proteins associated with efflux, membrane permeability, and stress response pathways. The mutants selected for ceftazidime/avibactam resistance still maintained pathogenicity in mice models, highlighting the need for vigilant monitoring of resistance development in clinical settings. Additional combinations of beta-lactams with beta-lactamase inhibitors or enhancers showed potential for overcoming ceftazidime/avibactam resistance.
Ceftazidime/avibactam uniquely demonstrates activity against both KPC and OXA-48-like carbapenemase-expressing Enterobacterales. Clinical resistance to ceftazidime/avibactam in KPC-producers was foreseen in in-vitro resistance studies. Herein, we assessed the resistance selection propensity of ceftazidime/avibactam in K. pneumoniae expressing OXA-48-like beta-lactamases (n = 10), employing serial transfer approach. Ceftazidime/avibactam MICs (0.25-4 mg/L) increased to 16-256 mg/L after 15 daily-sequential transfers. The whole genome sequence analysis of terminal mutants showed modifications in proteins linked to efflux (AcrB/AcrD/EmrA/Mdt), outer membrane permeability (OmpK36) and/or stress response pathways (CpxA/EnvZ/RpoE). In-vitro growth properties of all the ceftazidime/avibactam-selected mutants were comparable to their respective parents and they retained the ability to cause pulmonary infection in neutropenic mice. Against these mutants, we explored the activities of various combinations of beta-lactams (ceftazidime or cefepime) with structurally diverse beta-lactamase inhibitors or a beta-lactam enhancer, zidebactam. Zidebactam, in combination with either cefepime or ceftazidime, overcame ceftazidime/avibactam resistance (MIC range 0.5-8 mg/L), while cefepime/avibactam was the second best (MIC: 0.5-16 mg/L) in yielding lower MICs. The present work revealed the possibility of ceftazidime/avibactam resistance in OXA-48-like K. pneumoniae through mutations in proteins involved in efflux and/or porins without concomitant fitness cost mandating astute monitoring of ceftazidime/avibactam resistance among OXA-48 genotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据